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ABSTRACT
MiRNAs are important regulators of gene expression
and are frequently deregulated under pathologic con-
ditions. They are highly stable in bodily fluids which
makes them feasible candidates to become mini-
mally invasive biomarkers. In fact, several studies
already proposed circulating miRNA-based biomark-
ers for different types of neoplastic, cardiovascular
and degenerative diseases. However, many of these
studies rely on small RNA sequencing experiments
that are based on different RNA extraction and pro-
cessing protocols, rendering results incomparable.
We generated liqDB, a database for liquid biopsy
small RNA sequencing profiles that provides users
with meaningful information to guide their small RNA
liquid biopsy research and to overcome technical and
conceptual problems. By means of a user-friendly
web interface, miRNA expression profiles from 1607
manually annotated samples can be queried and ex-
plored at different levels. Result pages include down-
loadable expression matrices, differential expression
analysis, most stably expressed miRNAs, cluster
analysis and relevant visualizations by means of box-
plots and heatmaps. We anticipate that liqDB will be
a useful tool in liquid biopsy research as it provides
a consistently annotated large compilation of exper-
iments together with tools for reproducible analy-
sis, comparison and hypothesis generation. LiqDB
is available at http://bioinfo5.ugr.es/liqdb.
INTRODUCTION
Despite the well-established usage of blood and urine in dis-
ease detection and diagnosis, the term liquid biopsy does
not appear in PubMed until 2011 in a work where breast
cancer patients response to trastuzumab was monitored us-
ing circulating epithelial tumour cells (CETC) (1). Since
then, liquid biopsy has become a rapidly growing research
field based on the extraction of non-solid biological mate-
rial such as blood, saliva, urine or cerebrospinal fluid that
can be sampled in a minimally invasive way. From this ma-
terial can then be extracted, among others: protein-bound
RNA molecules, vesicles such as exosomes, cell-free DNA
(cfDNA), circulating tumour cells (CTC) and platelets that
can be used for clinical purposes. More specifically, geno-
types and methylation states of extracted DNA molecules
or the abundance of RNA molecules can be screened to
search for non-invasive biomarkers that allow for early di-
agnosis, treatment monitoring, tumour staging, relapse risk
assessment and prognosis (2).
Since microRNAs were discovered in humans in 2000,
their functional role as post-transcriptional repressors has
been extensively studied. MicroRNA expression levels are
generally altered in several pathologies including cancer
(3), so they hold great potential as disease biomarkers at
tissue level. Furthermore, microRNAs have been detected
in virtually all bodily fluids either within exosomes (4) or
bound to proteins that protect them from RNAse activity
(5), both of which increase their stability and therefore their
detectability. If the release of most microRNAs is fairly ran-
dom (6), the assumption is that intracellular changes can be
detected in the different biofluids as well, which allows for
potential applicability as diagnostic, prognostic and predic-
tive biomarkers. In fact, several studies have already used
this approach to proposemiRNA-based biomarkers for dif-
ferent types of neoplastic (7,8), cardiovascular (9) and de-
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generative disease (10). Many of these studies rely on small
RNA sequencing experiments but differences in sample col-
lection, extraction, storage, processing, library preparation
and sequencing method can have a strong impact on the
abundance of detected miRNAs (11). Highly parametrized
computational tools used for data analysis are yet another
source of fluctuation in the obtained expression values.
Note that most of these issues are not inherent to sequenc-
ing approaches, as othermethods such as qRT-PCRare also
affected by this panoply of possible confounding variables.
Furthermore, no endogenous small RNA has been estab-
lished to normalize abundance in plasma, although syn-
thetic spike-in molecules have been proposed to address this
problem (12).
In order to help to overcome the problems described
above we developed liqDB, a database for small RNA ex-
pression profiles in bodily fluids. Unlike other literature-
based resources such as miRandola (13) or ExoCarta (14),
liqDB contains small RNA expression profiles of 1607man-
ually annotated samples from SRA, generated by means of
a reproducible bioinformatics protocol. The database can
be queried in different ways exploring 19 different biofluids
or the impact of six variables like health state or RNA ex-
traction method. Users can perform customised queries or
compare uploaded data to sample sets from the database.
Most important results are: downloadable expression ma-
trixes, differentially expressed microRNAs and most stably
expressed microRNAs. Visualisation of the output includes
interactive RNA distribution boxplots and heatmaps (15).
A strong increase in liquid biopsy small RNA research is to
be expected over the next years and we are confident that
liqDB can play a central role in organising, classifying and
offering this information to researchers in the field.
SCOPE AND WEB INTERFACE
Scope
Currently, the database contains a total of 1607 coherently
annotated sRNA-seq samples from 30 publically available
SRA studies corresponding to 19 different biofluids. The
sample annotations provided by the original authors were
manually curated and unified to include relevant variables
such as biofluid, gender, health state (healthy/not healthy),
RNAextraction protocol, exosome isolation (yes or no) and
RNA library preparation protocol, all of which can have an
impact on the miRNA abundance acting as confounding
variables for the variable of interest, usually related to the
health state.
The database can be used and queried in five different
ways:
• Browse studies: For each of the 30 SRA projects in the
database, results were pre-calculated. Differential expres-
sion is calculated whenever possible for the relevant vari-
ables (mostly health state and gender although RNA
extraction, library preparation methods and different
biofluids were analysed for some studies). Additionally
to themiRNA expression profiles, other results are gener-
ated (seeResult Page below for more details). Frequently,
users are interested in a particular project focused on a
specific cancer or biofluid and this information can be
quickly accessed in this way.
• Search samples: Users can customize a set of samples
by selecting query values for 6 variables and a thresh-
old number of miRNA-mapping reads in order to im-
prove confidence in the results. The Basic statistics sec-
tion can help users find the most adequate threshold for
their desired query. At a second stage, the preselected
set of samples can be manually refined. Most highly ex-
pressed, most fluctuating and most stably expressed mi-
croRNAs can be obtained, among other features. The
downloadable expression matrix can be used for further
downstream analysis (see Result Page below for more de-
tails).
• Search miRNAs: Users interested in one particular
miRNA can search it and analyse its expression values
as a function of the different variables.
• Compare two datasets: Similarly to the selection of one
set, the user can define two different sets of samples. Ad-
ditionally to the general output results, differentially ex-
pressed microRNAs between the two sets will be calcu-
lated.
• Compare with user data: This tool allows comparison
of a selected set of samples from the database to user-
provided samples.Users should first profile their sequenc-
ing reads input file using sRNAbench from the sRNA-
toolbox server (16). Subsequently, the job IDs can be used
as input as well as relevant query variables to generate a
standard result page including differential expression be-
tween database and uploaded samples.
Results pages
The standard results page includes the sections described
below.
• Overview/query results: The full annotation of all se-
lected samples.
• miRNA profiles: a sortable and searchable expression
matrix with adjusted RPM values (Reads Per Million),
a boxplot of the 20 most abundant microRNAs, a pie-
chart showing the relative frequency of the 10 most abun-
dant microRNAs, the 20 microRNAs with highest coeffi-
cient of variation (CV) and the 20 microRNAs with low-
est CV. The CV is calculated as the standard deviation of
the adjusted RPM expression values divided by the mean
value. It is a standardized measure of the dispersion of
RPM values which does not depend on the magnitude
and therefore allows to compare the dispersion of highly
and lowly abundant microRNAs. The expression of mi-
croRNAs with lowest CV is less affected by the different
variables in the analysis and could be used as reference
microRNAs to normalize or standardize qPCR valida-
tion experiments.
• sRNA types distribution: Proportions of reads assigned
to each of the different small RNA types (miRNA,
tRNA, yRNA, ribosomal RNA, etc) are shown in a ta-
ble and the 10 most frequent categories are depicted in
boxplots. The category ‘Un-assigned’ contains genome
mapped reads which could not be assigned to any anno-
tation.
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• Species Distribution: A high number of reads that can-
not be mapped to the genome can indicate contamina-
tion or the presence of genetic material from symbionts
or parasites. In order to address this question, liqDB sum-
marizes the mapping to the human genome, virus and
bacteria collections showing the relative frequencies of
reads assigned to the different species. If a read maps to
more than 20 loci in the genome, it will not be used for
expression profiling. Those reads get the label ‘HR’ for
highly redundant. hsa HR will therefore refer to the rela-
tive frequency of reads thatmapmore than 20 times to the
human genome. Furthermore, a read can map with the
same quality (number of mismatches and length) to dif-
ferent indexes. In this cases, a new category is generated
mentioning all genomes separated by ‘-’. For example hu-
man virus-hsawill refer to the number and percentage of
reads that map both to the human genome and the virus
collection.
• Download: Expression matrices are available for down-
load as well as a zip file with the complete analysis.
• Differential Expression: if available, pre-calculated study
specific comparisons or generated from user-provided
groups are displayed. Differentially expressed microR-
NAs are calculated using two-sided t-test on Reads Per
Million values. Subsequently, p-values are corrected for
multiple testing applying the Bonferroni procedure. Box-
plots of the most abundant differentially expressed mi-
croRNAs are displayed and a link to a heatmap is pro-
vided. Files for the complete analysis can be found in
the download section. Note that the output for ‘Com-
pare two datasets’ (user selected sets) will always con-
tain one pairwise comparison, while the differential ex-
pression section in ‘Browse studies’ might contain several
pairwise comparisons if more than two groups exist for
one variable (e.g. SRP061240 with three different cancer
types and healthy controls).
The microRNA search generates one output page with
several boxplots depicting the expression of themicroRNAs
as a function of the different variables.
DATA AND METHODS
Database construction
All expression values and metadata were uploaded to a
MySQL database. The interactive web interface was imple-
mented using the Django framework together with Boot-
strap, javascript and the plotly package (Plotly Technolo-
gies, 2015, Collaborative data science, https://plot.ly) for in-
teractive data visualization. A backend java program con-
nected to the database calculates and prepares the raw re-
sults files. Apache2 was chosen as HTTP webserver.
Data collection and processing
Suitable data was searched using the NCBI based SRA
(short read archive) repository and publications included
in PubMed. The data was downloaded in sra format and
converted with fastq-dump to standard fastq format. For
expression profiling, sRNAbench, the successor program
of miRanalyzer (17) was used. After removing adapter or
barcode sequences, the obtained clean reads are collapsed
into unique reads (UR) assigning a read count (RC) to
each unique read sequence. By means of bowtie1 (18) the
collapsed reads are mapped simultaneously to the human
genome (GRCh38, patch 10), a collection of bacteria (Bac-
teria Ensembl, Release 39) as well as to human virus se-
quences (Human virus from EnsemblGenomes) and only
the bestmapping reads are retained as described before (17).
One mismatch within the 19 nt seed region was allowed in
the mapping process.
The genome mapped reads are then assigned successively
to several reference libraries in a hierarchical way in the ex-
act order described below. After each step, reads can only
be assigned to one library in order to avoid cross-library
matches. For example, after mapping miRNA reads, those
are removed and cannot be assigned to tRNAs or other
small RNA annotations.
• miRNAs: miRBase v22 (19) and miRGeneDB v.2
(Fromm et al., MirGeneDB2.0: the curated microR
NA Gene Database. bioRxiv, https://doi.org/10.1101/
258749). We produced a merged annotation using miR-
Base names adding miRGeneDB sequences if those are
not annotated in miRBase. Human and several virus an-
notations are used for profiling.
• tRNAs: GtRNAdb, a genomic tRNA database (20)
• vault-RNA, yRNA and guide RNAs extracted fromRef-
Seq (21)
• Non-coding RNAs from Ensembl (22)
• Non-coding RNAs from RNAcentral release 9 (23)
• RNA sequences of coding genes from Ensembl (Release
91) (22)
Please note that no further filtering of the miRBase ref-
erence sequences was performed which implies that, very
likely, false positive miRNAs exist in the database. An ex-
ample of this is miR-1246, which turned out to be a U2
small nuclear RNA (RNU2-1) fragment useful to discrimi-
nate tumours from controls (24).
Expression values and relative frequencies
The microRNA expression values are calculated based on
raw read counts adjusted for multiple mapping. The expres-
sion matrixes in RPM or adjusted raw read counts can be
downloaded. The latter is the required format for most dif-
ferential expression packages like DEseq (25) and edgeR
(26).
WORKING EXAMPLES
The influence of library preparation protocols on the mi-
croRNA profiles
The influence of different library preparation protocols on
plasma-derived exosomal RNA frequencies was first stud-
ied in 2013 by Huang et al. (27). These authors report
that the five most abundant microRNAs account for 49%
of all miRNA mapped reads. Since this study is available
at liqDB, we can replicate these results by simply click-
ing on Browse liqDB, Browse studies, finding this study
(SRP020486) and then navigating to the miRNA Profiles
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Figure 1. A schematic overview of liqDB. (A) the database can be queried in five different ways, either by browsing pre-calculated content or by instant
processing of user-defined sets of samples. (B) liqDB was populated with 1607 samples from 19 different biofluids. The profiling of the data is carried out
by means of sRNAbench (16) using both miRBase and miRGeneDB as annotations. (C) The general output consists of several sections, including miRNA
profiles, differential expression (only if applicable) and download (shown in the figure).
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A Differentially expressed miRNAs in SRP020486
B  Differentially expressed miRNAs in plasma NEBNext vs Illumina
C Heatmap of plasma samples labelled by library construction protocol
Figure 2. (A) Differentially expressed genes for three different library preparation protocols. (B) Differentially expressed miRNAs between NEBnext and
Illumina protocol using all plasma samples in liqDB. (C) Most Illumina samples (bright blue) cluster together except for two of them in the middle of the
NEBnext cluster (dark blue).
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tab. In the miRNA profiles table it can be confirmed that
liqDB lists the same five miRNAs as the most frequent
to make up for 46% of miRNA mapped reads. Small dif-
ferences are likely due to different miRBase versions as
well as the inclusion of miRGeneDB in liqDB. Figure 2A
shows the differentially expressedmiRNAs detected for this
study, i.e. the miRNAs which are highly influenced by the
library preparation protocol. Since there are only two Illu-
mina samples, statistical significance can only result from
Bioo Scientific (NEXTflex) vs. NEBnext protocol compar-
isons. Hsa-miR-128 is the most expressed microRNA that
is highly affected by the protocol. Figure 2A gives a me-
dian RPM for NEBnext protocol of 237 658 (243 837 in
the original article) while NEXTflex only yields 4655 (4569)
RPM, nearly 2 orders of magnitude below. RPM values
from liqDB and the original article are therefore nearly
identical.
However, since many more samples are included in
liqDB, we can extend this analysis to a larger query in
order to increase confidence in the results. For instance,
we can select plasma from all healthy subjects that used
miRNeasy RNA extraction and compare the samples that
applied Illumina library preparation protocol to those that
used NEBnext. To do so, we go to Compare datasets >
Compare two sets of samples and we set the selectors (see
Figure 1A) for both groups following the desired parame-
ters. We included a minimum threshold of 200 000 miRNA
reads to increase the robustness of the outcome and then
proceeded with all samples. While this comparison yields
three out of six most abundant microRNAs in common
with the SRP020486 results, it also reveals that 11 out of the
20 most abundant microRNAs are differentially expressed.
This confirms again that the miRNA abundance in plasma
is strongly affected by the library preparation protocol. The
hierarchical clustering (see Figure 2C) shows as well that
samples are grouped mostly by library protocol, although
there is also one cluster with NEBnext and Illumina sam-
ples which indicates the existence of other variables that in-
fluence the miRNA expression profiles.
Recently, the influence of sample processing in miRNA
sequencing was evaluated on a large scale study among nine
different laboratories (28) confirming the strong impact of
library preparation and other variables.
Finding least variable miRNAs in serum samples
For some downstream validation experiments such as qRT-
PCR, it may be relevant to know which miRNAs are most
stably expressed in order to use them as reference. In this
case, we queried the database for serum samples using the
following workflow: Browse liqDB > Search samples; then
a series of selectors are displayed. For these, we chose
serum for Fluid, Both for Sex, True for Healthy Subjects,
miRNeasy for RNA extraction Protocol and NEBnext for
RNA Library preparation and then clicked Filter. To avoid
effect of other confounding factors, we limited the analy-
sis to only one extraction and one library protocol. Subse-
quently, we kept all samples for analysis by clicking on Pro-
ceed with all samples. In the results page, we then navigate
to themiRNAProfiles tab where the last graph will show the
miRNAs with the lowest variability for the specified query
(Figure 3A).
Comparing two sets of samples: plasma of men versus plasma
of women
In order to compare two sets of samples in the most realis-
tically possible way, potential confounding variables should
be controlled for both sets. In this case we analysed differ-
ences in plasma between men and women. To do so, we first
navigated to Compare Datasets> Compare two sets of sam-
ples. Similarly to the previous example, we will find two sets
of selectors: one for the first group of our comparison and
another for the second (See Figure 1A). For both selectors,
we set Fluid to plasma, Healthy subjects to True, Extrac-
tion protocol to miRNeasy and Library protocol to NEB-
next; for Group 1 Sex will be male and for Group 2 female.
Once in the page of results, we navigated to the Differential
Expression tab.
The boxplots graph (see Figure 3B) displays the 10 dif-
ferentially expressed miRNAs with the highest expression
values and then individual samples can be clustered and vi-
sualized in a heatmap (see Figure 3C).
CONCLUSIONS AND OUTLOOK
Given that miRNAs are highly stable and relatively de-
tectable in most biofluids, it is safe to assume that they
will play important roles in the fast growing field of liq-
uid biopsy. Many projects use high-throughput sequenc-
ing approaches in the exploratory phase of biomarker dis-
covery making the data publicly available through reposi-
tories such as SRA or GEO. In order to structure, orga-
nize and unify this vast amount of information into an in-
teractive database, major problems like incomplete or in-
consistent sample annotations need to be solved. liqDB is
the first database that provides researchers from the liquid
biopsy field with browse- and downloadable coherently an-
notated datasets generated using the same bioinformatics
protocol. Furthermore the database allows the comparison
to external data therefore enabling the generation and test-
ing of new hypothesis. We also encourage researchers to
share their data through SRA and submit the accession to
liqDB or just to point out any overlooked SRAprojects that
might be suitable for inclusion.
In the short term, there are three main improvements
planned. First, other small RNA derived sequences like
isomiRs or fragments of tRNA, yRNA or vault-RNA
molecules will be included in liqDB as they all might have
biomarker potential (29). Secondly, we will add different
quality related flags to the sample annotations so the user
can decide to exclude lower quality samples (30). And fi-
nally, since differential expression is one of the key anal-
ysis for gene expression data, we will improve this feature
by adding online support for DEseq (25) and EdgeR (26).
These additions will be useful for exploratory analysis of the
data as well as for the analysis of confounding variables.
In summary, we anticipate that liqDBwill be a useful tool
for liquid biopsy researchers as it can help to develop stan-
dardized and stable protocols opening the door to repro-
ducible reanalysis, realistic comparison and hypothesis gen-
eration, important tasks to avoid unnecessary validation of
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A   Exploring least variable miRNAs
B   Differentially expre ssed microRNAs: male vs female
C   Heatmap from two user-defined sets of samples
Figure 3. Examples from the web interface. (A) Boxplot of least variable miRNAs, candidates to control downstream validation. (B) Example of differ-
entially expressed miRNAs boxplots. (C) Example of heatmap displaying clustering of plasma samples using differentially expressed miRNAs. Men are
marked in dark blue and women in bright. Generated using heatmaply (15).
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defective biomarker candidates which could prevent the dis-
covery of actually useful biomarkers.
ACKNOWLEDGEMENTS
The authors acknowledge the usage of the computational
infrastructure of the Computational Epigenomics Lab of
the University of Granada.
FUNDING
European Union’s Horizon 2020 research and innova-
tion programme under the Marie Skłodowska-Curie [grant
agreement ELBA, 765492 to M.H. and D.K.L.]; Span-
ish Government [AGL2017-88702-C2-2-R to M.H.]; Insti-
tuto de Salud Carlos III, FEDER funds [PIE16/00045 to
J.A.M.]; Chair ‘Doctors Galera-Requena in cancer stem
cell research’ (to J.A.M.); Ministry of Education of Spain
[FPU13/05662 to R.L. and IFI16/00041 to E.A.]. Fund-
ing for open access charge: Instituto de Salud Carlos III
(FEDER funds) [PIE16/00045].
Conflict of interest statement.None declared.
REFERENCES
1. Pachmann,K., Camara,O., Kroll,T., Gajda,M., Gellner,A.K.,
Wotschadlo,J. and Runnebaum,I.B. (2011) Efficacy control of therapy
using circulating epithelial tumor cells (CETC) as “liquid biopsy”:
trastuzumab in HER2/neu-positive breast carcinoma. J. Cancer Res.
Clin. Oncol., 137, 1317–1327.
2. Heitzer,E., Perakis,S., Geigl,J.B. and Speicher,M.R. (2017) The
potential of liquid biopsies for the early detection of cancer. NPJ
Precis. Oncol., 1, 36.
3. Esquela-Kerscher,A. and Slack,F.J. (2006) Oncomirs –– microRNAs
with a role in cancer. Nat. Rev. Cancer, 6, 259–269.
4. Michael,A., Bajracharya,S., Yuen,P., Zhou,H., Star,R., Illei,G. and
Alevizos,I. (2010) Exosomes from human saliva as a source of
microRNA biomarkers. Oral Dis., 16, 34–38.
5. Arroyo,J.D., Chevillet,J.R., Kroh,E.M., Ruf,I.K., Pritchard,C.C.,
Gibson,D.F., Mitchell,P.S., Bennett,C.F., Pogosova-Agadjanyan,E.L.,
Stirewalt,D.L. et al. (2011) Argonaute2 complexes carry a population
of circulating microRNAs independent of vesicles in human plasma.
Proc. Natl. Acad. Sci. U.S.A, 108, 5003–5008.
6. Koppers-Lalic,D., Hackenberg,M., Bijnsdorp,I.V., van
Eijndhoven,M.A.J., Sadek,P., Sie,D., Zini,N., Middeldorp,J.M.,
Ylstra,B., de Menezes,R.X. et al. (2014) Nontemplated nucleotide
additions distinguish the small RNA composition in cells from
exosomes. Cell Rep., 8, 1649–1658.
7. Yuan,T., Huang,X., Woodcock,M., Du,M., Dittmar,R., Wang,Y.,
Tsai,S., Kohli,M., Boardman,L., Patel,T. et al. (2016) Plasma
extracellular RNA profiles in healthy and cancer patients. Sci. Rep.,
6, 19413.
8. Huang,X., Yuan,T., Tschannen,M., Sun,Z., Jacob,H., Du,M.,
Liang,M., Dittmar,R.L., Liu,Y., Liang,M. et al. (2013)
Characterization of human plasma-derived exosomal RNAs by deep
sequencing. BMC Genomics, 14, 319.
9. Uhlmann,S., Mracsko,E., Javidi,E., Lamble,S., Teixeira,A.,
Hotz-Wagenblatt,A., Glatting,K.-H. and Veltkamp,R. (2017)
Genome-Wide analysis of the circulating miRNome after cerebral
ischemia reveals a Reperfusion-Induced MicroRNA cluster. Stroke,
48, 762–769.
10. Seco-Cervera,M., Gonza´lez-Rodrı´guez,D., Iba´n˜ez-Cabellos,J.S.,
Peiro´-Chova,L., Pallardo´,F.V. and Garcı´a-Gime´nez,J.L. (2018) Small
RNA-seq analysis of circulating miRNAs to identify phenotypic
variability in Friedreich’s ataxia patients. Sci. Data, 5, 180021.
11. Correia,C.N., Nalpas,N.C., McLoughlin,K.E., Browne,J.A.,
Gordon,S. V., MacHugh,D.E. and Shaughnessy,R.G. (2017)
Circulating microRNAs as potential biomarkers of infectious disease.
Front. Immunol., 8, 118.
12. Kroh,E.M., Parkin,R.K., Mitchell,P.S. and Tewari,M. (2010)
Analysis of circulating microRNA biomarkers in plasma and serum
using quantitative reverse transcription-PCR (qRT-PCR).Methods,
50, 298–301.
13. Russo,F., Di Bella,S., Vannini,F., Berti,G., Scoyni,F., Cook,H.V.,
Santos,A., Nigita,G., Bonnici,V., Lagana`,A. et al. (2018) miRandola
2017: a curated knowledge base of non-invasive biomarkers. Nucleic
Acids Res., 46, D354–D359.
14. Mathivanan,S. and Simpson,R.J. (2009) ExoCarta: a compendium of
exosomal proteins and RNA. Proteomics, 9, 4997–5000.
15. Galili,T., O’Callaghan,A., Sidi,J. and Sievert,C. (2018) heatmaply: an
R package for creating interactive cluster heatmaps for online
publishing. Bioinformatics, 34, 1600–1602.
16. Rueda,A., Barturen,G., Lebro´n,R., Go´mez-Martı´n,C., Alganza,A´.,
Oliver,J.L. and Hackenberg,M. (2015) sRNAtoolbox: an integrated
collection of small RNA research tools. Nucleic Acids Res., 43,
W467–W473.
17. Hackenberg,M., Rodrı´guez-Ezpeleta,N. and Aransay,A.M. (2011)
miRanalyzer: an update on the detection and analysis of microRNAs
in high-throughput sequencing experiments. Nucleic Acids Res., 39,
W132–W138.
18. NCBI Resource Coordinators. (2017) Database resources of the
National Center for Biotechnology Information. Nucleic Acids Res.,
45, D12–D17.
19. Kozomara,A. and Griffiths-Jones,S. (2014) miRBase: annotating
high confidence microRNAs using deep sequencing data. Nucleic
Acids Res., 42, D68–D73.
20. Chan,P.P. and Lowe,T.M. (2016) GtRNAdb 2.0: an expanded
database of transfer RNA genes identified in complete and draft
genomes. Nucleic Acids Res., 44, D184–D189.
21. Pruitt,K.D., Tatusova,T. and Maglott,D.R. (2007) NCBI reference
sequences (RefSeq): a curated non-redundant sequence database of
genomes, transcripts and proteins. Nucleic Acids Res., 35, D61–D65.
22. Zerbino,D.R., Achuthan,P., Akanni,W., Amode,M.R., Barrell,D.,
Bhai,J., Billis,K., Cummins,C., Gall,A., Giro´n,C.G. et al. (2018)
Ensembl 2018. Nucleic Acids Res., 46, D754–D761.
23. Consortium,The RNAcentral (2017) RNAcentral: a comprehensive
database of non-coding RNA sequences. Nucleic Acids Res., 45,
D128–D134.
24. Baraniskin,A., No¨pel-Du¨nnebacke,S., Ahrens,M., Jensen,S.G.,
Zo¨llner,H., Maghnouj,A., Wos,A., Mayerle,J., Munding,J., Kost,D.
et al. (2013) Circulating U2 small nuclear RNA fragments as a novel
diagnostic biomarker for pancreatic and colorectal adenocarcinoma.
Int. J. Cancer, 132, E48–E57.
25. Anders,S. and Huber,W. (2010) Differential expression analysis for
sequence count data. Genome Biol., 11, R106.
26. Robinson,M.D., McCarthy,D.J. and Smyth,G.K. (2010) edgeR: a
Bioconductor package for differential expression analysis of digital
gene expression data. Bioinformatics, 26, 139–140.
27. Huang,X., Yuan,T., Tschannen,M., Sun,Z., Jacob,H., Du,M.,
Liang,M., Dittmar,R.L., Liu,Y., Liang,M. et al. (2013)
Characterization of human plasma-derived exosomal RNAs by deep
sequencing. BMC Genomics, 14, 319.
28. Giraldez,M.D., Spengler,R.M., Etheridge,A., Godoy,P.M.,
Barczak,A.J., Srinivasan,S., De Hoff,P.L., Tanriverdi,K.,
Courtright,A., Lu,S. et al. (2018) Comprehensive multi-center
assessment of small RNA-seq methods for quantitative miRNA
profiling. Nat. Biotechnol., 36, 746.
29. Balatti,V., Pekarsky,Y. and Croce,C.M. (2017) Role of the
tRNA-Derived small RNAs in cancer: New potential biomarkers and
target for therapy. Adv. Cancer Res., 135, 173–187.
30. Koppers-Lalic,D., Hackenberg,M., de Menezes,R., Misovic,B.,
Wachalska,M., Geldof,A., Zini,N., de Reijke,T., Wurdinger,T., Vis,A.
et al. (2016) Non-invasive prostate cancer detection by measuring
miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget,
7, 22566–22578.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/D
1/D
113/5144140 by U
niversidad de G
ranada - Biblioteca user on 20 January 2020
